Notice NOT-AI-24-062 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-054 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-055 from the NIH Guide for Grants and Contracts

Notice NOT-GM-24-043 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-24-254 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notifies recipient organizations holding specific types of NIH grants, listed within the Activity Code section above, that applications for change of recipient organization may be submitted to this NOFO. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this NOFO, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

Funding Opportunity PA-24-253 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization status, often referred to in this announcement as Successor-In-Interest, may be submitted to this NOFO. Applications for change of recipient organization status are considered prior approval requests (as described in Section 8.1.2.8 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although successor-in-interest requests may be submitted through this NOFO, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

Notice NOT-DC-24-035 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-120 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-080 from the NIH Guide for Grants and Contracts

Notice NOT-AR-24-018 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-25-020 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invitesapplications for the Claude D. Pepper Older Americans Independence Centers (OAICs) award. The goal of the OAIC program is to establishcenters of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. OAIC awards are designed to develop or strengthen programs that focus on, and sustain progress in, a key area of aging research related to the mission of the OAIC program.

Funding Opportunity PAR-24-241 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to build upon the NIMH supported APN and further expand it into APN2 to include larger, more comprehensive studies that address current gaps in the field. The CC created under this initiative will further facilitate network-wide collaborative activities which will enhance the value of the unique data resource to be created by the network projects, develop much needed guidance to the scientific community and promote career development and research capacity building for investigators from low resource settings around the globe.

Funding Opportunity PAR-24-240 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) seeks applications proposing coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of African ancestry on the African continent to advance the important goal of global mental health equity. This Notice of Funding Opportunity (NOFO) is one of several NOFOs participating in a program called, Ending Disparities in Mental Health (EDIfy-MH).

Competitive: CK Group: CK Group are working in partnership with Nxera Pharma to recruit two Computational Chemists to join their Computational Chemistry team. Applications are welcomed from candidates... Cambridge

Notice NOT-MH-24-280 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HS-24-003 from the NIH Guide for Grants and Contracts. To advance the field of patient-centered clinical decision support through research that tests tools and resources in real-world settings.

Funding Opportunity RFA-HL-25-010 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity for a Clinical Coordinating Center is to support a clinical trial which will test intervention(s) to reduce the progression of coronary atherosclerosis among young adults under the age of fifty years old who are at low or borderline 10-year risk ( 7.5%) for their first an atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). This opportunity will support a two-phased primary prevention clinical trial that will first efficiently screen the appropriate population eligible for the intervention and second determine which intervention(s) are most efficacious at reducing the onset or slowing the progression of subclinical coronary atherosclerosis. It is expected that phase one will overlap with phase two. Trial participants who are identified as meeting the subclinical coronary atherosclerosis criteria for enrollment in the screening stage will be immediately enrolled in stage two even although stage one recruitment will continue until the trial is completely enrolled. It is expected that the trial will have three arms. One will be a control or comparison arm and the second and the third arm will test different interventions than the control arm. The control arm should be current guideline based behavioral interventions. One of the two non-control arms is expected to involvement pharmacological intervention(s) with definite evidence of efficacious for primary prevention in older high risk adults such as LDL- lowering therapy and the other arm may involve intervention(s) with less definite evidence of primary prevention efficacy in older adults The long range goal of this research strategy is to determine if earlier treatment prevents more CVD than current guideline recommended treatment. Applications for both a CCC and a DCC must be submitted on the same application due date for consideration by NHLBI.

Funding Opportunity RFA-HL-25-007 from the NIH Guide for Grants and Contracts. This NOFO will support applications to develop and implement a Data Coordinating Center (DCC) for a multi-site clinical trial among young adults without clinical atherosclerotic cardiovascular disease (ASCVD). It will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion NOFO that encourages applications for a collaborating Clinical Coordinating Center (RFA-HL-25-010). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC (RFA-HL-25-010) on implementation of the clinical trial community engagement and diversity plans, as well as reducing health inequities. Clinical trials using innovative designs such as platform trials, adaptive, and Bayesian designs are welcomed. Applications for both a DCC and a Clinical Coordinating Center (CCC) must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

From £43,210 with benefits, subject to skills and experience: The Francis Crick Institute: An exciting opportunity to be part of a pioneering biomedical research institute, dedicated to innovation and science. London (Central), London (Greater)

Competitive: CK Group: CK Group are working in partnership with Nxera Pharma to recruit for a Cheminformatician to join their Computational Chemistry team. Applications are welcomed from candidates... Cambridge